Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

868 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Highly active antiretroviral therapy restores CD4+ Vbeta T-cell repertoire in patients with primary acute HIV infection but not in treatment-naive HIV+ patients with severe chronic infection.
Cossarizza A, Poccia F, Agrati C, D'Offizi G, Bugarini R, Pinti M, Borghi V, Mussini C, Esposito R, Ippolito G, Narciso P. Cossarizza A, et al. Among authors: esposito r. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):213-22. doi: 10.1097/00126334-200403010-00001. J Acquir Immune Defic Syndr. 2004. PMID: 15076235 Clinical Trial.
Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
Mussini C, Pezzotti P, Govoni A, Borghi V, Antinori A, d'Arminio Monforte A, De Luca A, Mongiardo N, Cerri MC, Chiodo F, Concia E, Bonazzi L, Moroni M, Ortona L, Esposito R, Cossarizza A, De Rienzo B. Mussini C, et al. Among authors: esposito r. J Infect Dis. 2000 May;181(5):1635-42. doi: 10.1086/315471. Epub 2000 May 15. J Infect Dis. 2000. PMID: 10823763 Clinical Trial.
Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study.
Mussini C, Pezzotti P, Miró JM, Martinez E, de Quiros JC, Cinque P, Borghi V, Bedini A, Domingo P, Cahn P, Bossi P, de Luca A, d'Arminio Monforte A, Nelson M, Nwokolo N, Helou S, Negroni R, Jacchetti G, Antinori S, Lazzarin A, Cossarizza A, Esposito R, Antinori A, Aberg JA; International Working Group on Cryptococcosis. Mussini C, et al. Among authors: esposito r. Clin Infect Dis. 2004 Feb 15;38(4):565-71. doi: 10.1086/381261. Epub 2004 Jan 29. Clin Infect Dis. 2004. PMID: 14765351 Free article.
CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
Mussini C, Bedini A, Borghi V, Guaraldi G, Esposito R, Barchi E, Enilia R, Cozzi-Lepri A, Philips AN, Ortolani P, Bratt G, Eriksson LE, Sighinolfi L, Cossarizza A, d'Arminio Monforte A, De Luca A, Di Giambenedetto S, Antinori A; International Study Group on CD4-monitored Treatment Interruptions. Mussini C, et al. Among authors: esposito r. AIDS. 2005 Feb 18;19(3):287-94. AIDS. 2005. PMID: 15718839
Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+ T cell count after antiretroviral therapy in drug-naïve HIV-positive patients.
Nasi M, Pinti M, Bugarini R, Troiano L, Lugli E, Bellodi C, Mussini C, Borghi V, Trenti T, Balli F, Esposito R, Cossarizza A. Nasi M, et al. Among authors: esposito r. Immunogenetics. 2005 Oct;57(9):628-35. doi: 10.1007/s00251-005-0031-z. Epub 2005 Oct 18. Immunogenetics. 2005. PMID: 16158329
868 results